Is Survodutide Better Than Ozempic or Zepbound?
Survodutide's first Phase 3 trial in type 2 diabetes posted up to 13% weight loss in people who stayed on the drug. On paper, that makes it competitive. But the comparisons are cross-trial, far more patients stopped the drug for side effects than on placebo, and no regulator has approved it anywhere. For now, an approved drug like semaglutide or tirzepatide is the one that can help you this year.
SYNCHRONIZE-2, published October 1 in the New England Journal of Medicine, tested survodutide in 755 adults with type 2 diabetes over 76 weeks. Weight and HbA1c both fell well beyond placebo (the table below has the figures), and up to nearly 30% of patients reached a normal HbA1c. For a diabetes trial those are strong numbers, and they're the first Phase 3 evidence that a dual GLP-1 and glucagon agonist works at scale.
Why the glucagon piece matters
Survodutide activates two receptors instead of one. The GLP-1 half does what Ozempic and Wegovy do: it suppresses appetite and slows gastric emptying. The glucagon half, which Ozempic doesn't touch, is thought to raise energy expenditure and reduce liver fat. Tirzepatide (Zepbound, Mounjaro) also hits two receptors, but its second one is GIP. SYNCHRONIZE-2 is the first large-scale diabetes trial to show the glucagon pairing can approach the weight loss the GIP pairing already set.
An earlier 16-week Phase 2 trial hinted at this: at 1.8 mg weekly or higher, survodutide beat open-label semaglutide 1.0 mg on weight loss and matched it on HbA1c. SYNCHRONIZE-2 is what turns that hint into Phase 3 evidence.
How it stacks up against Ozempic and Zepbound
Across Phase 3 diabetes trials of weekly incretin shots, survodutide's 13.1% headline counts only people who stayed on the drug. Counting everyone who started, as the semaglutide figures below do, its best result is about level with semaglutide and below tirzepatide. HbA1c looks competitive. Every comparison below is cross-trial, and the trials had different populations, placebos, and durations. None of these drugs has been tested against another in a head-to-head Phase 3 trial.
| Drug (dose, trial) | Duration | Mean weight loss vs placebo | HbA1c reduction | Approval status |
|---|---|---|---|---|
| Survodutide 3.6 or 6.0 mg (SYNCHRONIZE-2) | 76 weeks | 13.1% vs 3.1% on drug | Not approved | |
| Semaglutide 2.4 mg (STEP 2) | 68 weeks | 9.6% vs 3.4% | 1.6 points, from 8.1% | Approved |
On the numbers alone, survodutide is at least in the conversation. But cross-trial math is the weakest form of drug comparison, and the Phase 2 study that pitted it against semaglutide was short and used a sub-maximal semaglutide dose. Counted the same way as the other trials, survodutide's weight loss sits closer to semaglutide's than to tirzepatide's.
Three gaps that keep it off the switch list
First, tolerability. In SYNCHRONIZE-2, 18% of patients on survodutide stopped the drug for side effects. Nausea, vomiting, diarrhea, and constipation drove most of it. That discontinuation rate is higher than what semaglutide and tirzepatide have shown in their diabetes Phase 3 trials.
Second, hard outcomes. GLP-1 drugs have shown a reduction of roughly 12% to 14% in major cardiac events across a decade of large outcomes trials. Survodutide's own outcomes trial, SYNCHRONIZE-CVOT, enrolled 5,508 adults with cardiovascular or kidney risk and hasn't reported results yet. Until it reports, there's no evidence that this drug matches the GLP-1 class on heart attacks, strokes, or death.
Third, availability. Survodutide isn't approved for diabetes or obesity in any country. The FDA has granted Fast Track status and a separate Breakthrough designation for fatty liver disease, and the EMA added it to its priority medicines scheme. None of that is approval. If you want a dual-receptor shot now, tirzepatide is the one you can get.
What to do in the meantime
If you have type 2 diabetes and are weighing a GLP-1, the practical answer hasn't changed. Semaglutide and tirzepatide are approved, available, and backed by cardiovascular outcomes data survodutide doesn't yet have. Starting one of them now, and seeing whether you tolerate it, is the choice with the most behind it.
Weight regain is the other reality. Across semaglutide and tirzepatide trials, people regained a large share of their lost weight after stopping, in proportion to how much they had lost. The same pattern is likely with survodutide, since these drugs work for as long as you take them.
Until a head-to-head trial, a cardiovascular readout, and an approval arrive, survodutide is a drug to keep watching.


